鷺燕醫藥(002788.SZ)半年度淨利潤升48.65%至1.21億元
格隆匯8月19日丨鷺燕醫藥(002788.SZ)發佈2019年半年度報告，實現營業收入71.73億元，同比增長34.97%；歸屬於上市公司股東的淨利潤1.21億元，同比增長48.65%；歸屬於上市公司股東的扣除非經常性損益的淨利潤1.20億元，同比增長46.51%；基本每股收益0.37元。
報告期內，公司管理層積極貫徹落實董事會從“橫向+縱向”發展戰略逐漸向“橫向+縱向+人工智能”三維戰略升級，從提供醫藥產品向提供健康服務升級，從五個傳統業務模塊(藥品分銷、零售、工業、醫療器械、醫養)向創新模塊(人工智能、第三方物流、電商)業務升級，將公司打造為中國知名的醫藥健康產品與服務提供商的發展戰略，內涵式發展與外延式擴張並舉，公司核心業務——福建省內醫藥分銷業務的市場份額、經營效率及盈利均實現持續提升和增長，四川、江西和海南等省份新併購醫藥分銷網絡已基本實現對全省主要區域二級以上醫療機構的覆蓋並形成競爭力，零售直營門店總數增加至204家，收購1家一級綜合性醫院，創新業務取得進展。
報告期內，公司發揮鷺燕“兩票制”經營經驗及優勢，抓住“兩票制”政策在全國推廣的機遇，繼續拓展布局四川、江西和海南省醫藥分銷網絡，截至報告期末，公司已完成四川省14個地市17家公司，江西省8個地市9家公司和海南省2家公司分銷網絡佈局，已基本實現對三個省主要區域二級以上醫療機構的覆蓋。公司通過增加對新併購企業的資金、業務等資源投入，加強企業文化建設、健全風險管控、調整組織架構、培訓人才團隊、提升內部管理、統一信息系統等投後整合工作，有效地提升了新成員企業的渠道覆蓋、經營管理能力和專業服務水平。至報告期末，公司在三個省份的醫藥分銷網絡已初見整合成效並形成競爭力。
報告期內，公司圍繞“人、貨、場、客”四大要素強化提升零售運營管理體系，深入開展批發零售一體化經營，藥品零售業務與批發業務協同漸見成效。截至2019年6月30日，公司在福建省內共有直營藥店204家(醫保店169家)，其中DTP藥房70家，基本覆蓋福建全省三級醫療機構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
